Plasma choline-containing phospholipids: Potential biomarkers for colorectal cancer progression

Metabolomics

Volumn 9, Issue 1, 2013, Pages 202-212

  Li, Song ^a   Guo, Bin ^a   Song, Jianwen ^a   Deng, Xiaoli ^a   Cong, Yusheng ^a   Li, Pengfei ^b   Zhao, Ke ^b   Liu, Lihong ^b   Xiao, Gang ^c   Xu, Feng ^d   Ye, Yingjiang ^d   Zhao, Zhenwen ^e   Yu, Menggang ^f   Xu, Yan ^e   Sang, Jianli ^a   Zhang, Junjie ^a  

^a Beijing Normal University   (China)

^b General Hospital of the Second Artillery Force of Chinese PLA   (China)

^c BEIJING HOSPITAL   (China)

^d PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

^e INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adenomatous polyps; Biomarkers; Colorectal cancer; Mass spectrometry; Phospholipids

Indexed keywords

LYSOPHOSPHATIDYLCHOLINE; SATURATED FATTY ACID; SPHINGOMYELIN; SPHINGOSYLPHOSPHORYLCHOLINE; UNSATURATED FATTY ACID;

ADENOMATOUS POLYP; ADULT; AGE; ARTICLE; CANCER DIAGNOSIS; CANCER GROWTH; CANCER STAGING; COLORECTAL CANCER; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIFFERENTIAL DIAGNOSIS; FEMALE; GENDER; HUMAN; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MALE; PHOSPHOLIPID BLOOD LEVEL; SENSITIVITY AND SPECIFICITY; TANDEM MASS SPECTROMETRY; TUMOR LOCALIZATION;

EID: 84872654995     PISSN: 15733882     EISSN: 15733890     Source Type: Journal    
DOI: 10.1007/s11306-012-0439-z     Document Type: Article

References (51)

1. Alexandrov, J. D., Mertens, B., Deelder, A. M., Rob, A. E. M., Tollenaar, P. M., & Thiele, H. (2009). Biomarker discovery in MALDI-TOF serum protein profiles using discrete wavelet transformation. Bioinformatics, 25, 643-649.
2. Berger, B. M., Robison, L., & Glickman, J. (2003a). Colon cancer-associated DNA mutations: Marker selection for the detection of proximal colon cancer. Diagnostic Molecular Pathology, 12, 187-192.
3. Berger, B. M., Vucson, B. M., & Ditelberg, J. S. (2003b). Gene mutations in advanced colonic polyps: Potential marker selection for stool-based mutated human DNA assays for colon cancer screening. Clinical Colorectal Cancer, 3, 180-185.
4. Brenner, H., Hoffmeister, M., & Haug, U. (2008). Family history and age at initiation of colorectal cancer screening. American Journal of Gastroenterology, 103, 2326-2331.
5. Calistri, D., Rengucci, C., Bocchini, R., Saragoni, L., Zoli, W., & Amadori, D. (2003). Fecal multiple molecular tests to detect colorectal cancer in stool. Clinical Gastroenterology and Hepatology, 1, 377-383.
6. Center, M. M., Jemal, A., Smith, R. A., & Ward, E. (2009). Worldwide variations in colorectal cancer. CA Cancer Journal for Clinicians, 59(6), 366-378.
7. Chen, W. D. Z., Han, J., Skoletsky, J., Shuber, A., Markowitz, S. D., et al. (2005). Detection in fecal DNA of colon cancer-specific methylation of the nonexpressed vimentin gene. Journal of the National Cancer Institute, 97, 1124-1132.
8. Dong, S. M., Traverso, G., Johnson, C., Vogelstein, B., Jen, J., et al. (2001). Detecting colorectal cancer in stool with the use of multiple genetic targets. Journal of the National Cancer Institute, 93, 858-865.
9. Doolittle, B. R., Emanuel, J., Tuttle, C., & Costa, J. (2001). Detection of the mutated K-Ras biomarker in colorectal carcinoma. Experimental and Molecular Pathology, 70, 289-301.
10. Fuchs, B., & Schiller, J. (2009). Lysophospholipids: Their generation, physiological role and detection. Are they important disease markers? Mini Reviews in Medicinal Chemistry, 9, 368-378.
11. Graler, M. H. (2010). Targeting sphingosine 1-phosphate (S1P) levels and S1P receptor functions for therapeutic immune interventions. Cellular Physiology and Biochemistry, 26, 79-86.
12. Guittet, L., Launoy, G., Mohammed, F., & Lieberman, D. A. (2010). Screening for colorectal cancer. New England Journal of Medicine, 362, 84-85.
13. Han, M., et al. (2008). Novel blood-based, five-gene biomarker set for the detection of colorectal cancer. Clinical Cancer Research, 14, 455-460.
14. Harrell, F. E., Jr, Lee, K. L., & Mark, D. B. (1996). Multivariable prognostic models: Issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Statistics in Medicine, 15, 361-387.
15. Huang, Z., Huang, D., Ni, S., Peng, Z., Sheng, W., & Du, X. (2010). Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. International Journal of Cancer, 127, 118-126.
16. Ikeda, A., Nishiumi, S., Shinohara, M., Yoshida, M., et al. (2011). Serum metabolomics as a novel diagnostic approach for gastrointestinal cancer. Biomedical Chromatography, 26(5), 548-558.
17. Imperiale, T. F., Ransohoff, D. F., Itzkowitz, S. H., Turnbull, B. A., & Ross, M. E. (2004). Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population. New England Journal of Medicine, 351, 2704-2714.
18. Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., & Forman, D. (2011). Global cancer statistics. CA Cancer Journal for Clinicians, 61(2), 69-90.
19. Jemal, A., Center, M. M., Ward, E., & Thun, M. J. (2009). Cancer occurrence. Methods in Molecular Biology, 471, 3-29.
20. Jemal, A., Siegel, R., Ward, E., Hao, Y., et al. (2008). Cancer statistics, 2008. CA Cancer Journal for Clinicians, 58, 71-96.
21. Jemal, A., Siegel, R., Xu, J., & Ward, E. (2010). Cancer statistics, 2010. CA Cancer Journal for Clinicians, 60, 277-300.
22. Kazama, S., Kitayama, J., Aoki, J., Mori, K., & Nagawa, H. (2010). Immunohistochemical detection of autotaxin (ATX)/lysophospholipase D (lysoPLD) in submucosal invasive colorectal cancer. Journal of Gastrointestinal Cancer, 42(4), 204-211.
23. Kim, H. J., Kang, H. J., Lee, S. T., et al. (2009). Identification of S100A8 and S100A9 as serological markers for colorectal cancer. Journal of Proteome Research, 8, 1368-1379.
24. Kountouras, J., Boura, P., & Lygidakis, N. J. (2000). New concepts of molecular biology for colon carcinogenesis. Hepato-Gastroenterology, 47, 1291-1297.
25. Lee, S. J., & Yun, C. C. (2010). Colorectal cancer cells: Proliferation, survival and invasion by lysophosphatidic acid. International Journal of Biochemistry & Cell Biology, 42, 1907-1910.
26. Leman, E. S., et al. (2007). Initial analyses of colon cancer-specific antigen (CCSA)-3 and CCSA-4 as colorectal cancer-associated serum markers. Cancer Research, 67, 5600-5605.
27. Lieberman, D. A. (2009). Screening for colorectal cancer. New England Journal of Medicine, 361, 1179-1187.
28. Liu, W., Wang, P., Li, Z., Xu, W., et al. (2009). Evaluation of tumour-associated antigen (TAA) miniarray in immunodiagnosis of colon cancer. Scandinavian Journal of Immunology, 69, 57-63.
29. Loitsch, S. M., Shastri, Y., & Stein, J. (2008). Stool test for colorectal cancer screening: It's time to move! J Clinical Laboratory, 54, 473-484.
30. Markowitz, S. D., & Bertagnolli, M. M. (2009). Molecular basis of colorectal cancer. New England Journal of Medicine, 361, 2449-2460.
31. Milhas, D., Clarke, C. J., & Hannun, Y. A. (2010). Sphingomyelin metabolism at the plasma membrane: Implications for bioactive sphingolipids. FEBS Letters, 584, 1887-1894.
32. Mills, G. B., & Moolenaar, W. H. (2003). The emerging role of lysophosphatidic acid in cancer. Nature Reviews Cancer, 3, 582-591.
33. Moshkowitz, M., & Arber, N. (2005). Differences in incidence and distribution of colorecetal cancer among races and ethnic societies: Lifestyle, genes or both? Digestion, 72, 219-222.
34. Muller, O. (2003). Identification of colon cancer patients by molecular diagnosis. Digestive Diseases, 21, 315-319.
35. Nixon, G. F., Mathieson, F. A., & Hunter, I. (2008). The multi-functional role of sphingosylphosphorylcholine. Progress in Lipid Research, 47, 62-75.
36. Noguchi, K., Herr, D., Mutoh, T., & Chun, J. (2009). Lysophosphatidic acid (LPA) and its receptors. Current Opinion in Pharmacology, 9, 15-23.
37. Peyruchaud, O. (2009). Novel implications for lysophospholipids, lysophosphatidic acid and sphingosine 1-phosphate, as drug targets in cancer. Anti-Cancer Agents in Medicinal Chemistry, 9, 381-391.
38. Pyne, N. J., & Pyne, S. (2010). Sphingosine 1-phosphate and cancer. Nature Reviews Cancer, 10, 489-503.
39. Ran, Y., Hu, H., Zhou, Z., Yu, L., Sun, L., Pan, J., et al. (2008). Profiling tumor-associated autoantibodies for the detection of colon cancer. Clinical Cancer Research, 14, 2696-2700.
40. Rivera, R., & Chun, J. (2008). Biological effects of lysophospholipids. Reviews of Physiology Biochemistry and Pharmacology, 160, 25-46.
41. Sarfaty, M., & Wender, R. (2007). How to increase colorectal cancer screening rates in practice. CA Cancer Journal for Clinicians, 57, 354-366.
42. Srivastava, S., Verma, M., & Henson, D. E. (2001). Biomarkers for early detection of colon cancer. Clinical Cancer Research, 7(5), 1118-1126.
43. Sung, J. J., Lau, J. Y., Goh, K. L., & Leung, W. K. (2005). Increasing incidence of colorectal cancer in Asia: Implications for screening. Lancet Oncol, 6, 871-876.
44. Tierney, R. P., Ballantyne, G. H., & Modlin, I. M. (1990). The adenoma to carcinoma sequence. Surgery, Gynecology & Obstetrics, 171, 81-94.
45. Umar, A., & Greenwald, P. (2009). Alarming colorectal cancer incidence trends: A case for early detection and prevention. Cancer Epidemiology, Biomarkers and Prevention, 18, 1672.
46. Wild, N., Andres, H., Rollinger, W., Krause, F., et al. (2010). A combination of serum markers for the early detection of colorectal cancer. Clinical Cancer Research, 16, 6111.
47. Wymann, M. P., & Schneiter, R. (2008). Lipid signalling in disease. Nature Reviews Molecular Cell Biology, 9, 162-176.
48. Xu, Y. (2002). Sphingosylphosphorylcholine and lysophosphatidylcholine: G protein-coupled receptors and receptor-mediated signal transduction. Biochimica et Biophysica Acta, 1582, 81-88.
49. Xu, Y., Shen, Z., Wiper, D. W., Wu, M., et al. (1998). Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers. JAMA, 280, 719-723.
50. Yang, M., Zhong, W. W., Srivastava, N., Slavin, A., et al. (2005). G protein-coupled lysophosphatidic acid receptors stimulate proliferation of colon cancer cells through the β-catenin pathway. Proceedings of the National Academy of Sciences of the USA, 102, 6027-6032.
51. Zhao, Z., Xiao, Y., Elson, P., Tan, H., et al. (2007). Plasma lysophosphatidylcholine levels: Potential biomarkers for colorectal cancer. Journal of Clinical Oncology, 25, 2696-2701.